Global Blood Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities

This Global Blood Therapeutics Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.

Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.

Executive BD thesis

Global Blood Therapeutics presents a practical BD-screening case because its returned pipeline contains 4 records and the deal search returned 1 transaction records. The lead returned asset is Inclacumab, associated with P-sel and Acute Coronary Syndrome, Myocardial Infarction, Peripheral Vascular Diseases, at Phase 2. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.

The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.

Partnering shortlist

Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.

Pipeline and evidence-package readout

The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.

Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.

Deal precedents and structure signals

The most relevant returned precedent is: Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology (2022-08-08). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.

Financial capacity and partnering pressure

• Global Blood Therapeutics, Inc. - 2021 Quarterly report: Global Blood Therapeutics, Inc. - 2021 Quarterly report PART I. – FINANCIAL INFORMATION As of the reported periods, Global Blood Therapeutics, Inc.'s liquidity position is highlighted by the following key figures: The company held $419,311 in cash and cash equivalents, complemented by $2,395 in restricted cash, cumulatively totaling $421,706 in overall cash and cash equivalents plus restricted cash. In comparison, the preceding period reflected a slightly lower liquidity stance with $384,716 in cash and cash equivalents, paired with an identical $2,395 in restricted cash, summing up to a total of $387,111. Global Blood Therapeutics, Inc. - 2021 Quarterly report Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS We are not profitable and have incur
• Global Blood Therapeutics, Inc. - 2021 Annual report: Global Blood Therapeutics, Inc. - 2021 Annual report Overview For the years ended December 31, 2020 and 2019 The comparison of the fiscal years ended December 31, 2020 and 2019 can be found in our annual report on Form 10-K for the fiscal year ended December 31, 2020 located within Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, which is incorporated herein by reference. Liquidity and Capital Resources We are not profitable and have incurred losses and negative cash flows from operations each year since our inception. We have financed our operations primarily through sale of equity securities and debt financing. As of December 31, 2021, we had $734.8 million in cash, cash equivalents and investments. In December 2019, we entered into

Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether Global Blood Therapeutics is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.

Recent events and outreach timing

• No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.

Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.

IP and diligence risk screen

The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.

Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.

Recommended outreach sequence

1. Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
2. Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
3. Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
4. Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
5. Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.

Bottom line

Global Blood Therapeutics merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate Inclacumab, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.

Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.